Post-COVID-19 asthenic syndrome

Close metadata

OBJECTIVE

To study the features of asthenic syndrome and the possibilities of its therapy in patients in the post-covid period.

MATERIAL AND METHODS

The study included 129 patients with an average age of 49.8±8.9 years who had undergone COVID-19 using a continuous sample method. Patients for the study were selected at the clinical bases of outpatient clinics in Samara (Russia) in July-August 2020. All patients signed an informed consent form prior to enrollment. Patients were randomized into two groups: in the main group (n=64), ethylmethylhydroxypyridine succinate (Neurox) was prescribed 1 tablet (125 mg) 3 times a day for 4 weeks; in the comparison group (n=65), medical drugs (MD) did not contain substances from the pharmacological group related to antihypoxants/antioxidants/nootropics. Three visits (V) were conducted: the first (V₁) — the period of inclusion, the second (V₂) — after 14 days, the third (V₃) — on the 28th day from the start of therapy. The dynamics of the general state (weakness, fatigue, concentration, dizziness, headache, sleep disorders) were evaluated on a visual-analog scale (VAS), the assessment of the subjective feeling of severity of asthenia (fatigue, physical and mental fatigue, decreased motivation and activity) — on Multidimensional Fatigue Inventory (MFI-20), cognitive functions — on Mini-Mental State Examination (MMSE), vegetative tone — according to the Kerdo index.

RESULTS

At the end of the study (V₃), statistically significant changes in indicators (VAS, MFI-20) were obtained only in the main group patients; no statistically significant differences were obtained for the Kerdo index. Analysis of the MMSE data revealed a decrease in cognitive functions in both groups, which may be associated with pseudocognitive deficits due to asthenia.

CONCLUSIONS

We have obtained evidence of a high incidence of asthenic syndrome after COVID-19. Against the background of taking Neurox, there was a decrease in the severity and expression of asthenia symptoms.

Keywords:

COVID-19

post-COVID-19 period

asthenia

asthenic syndrome

Neurox

Authors:

Zolotovskaya I.A.

Samara State Medical University

Shatskaia P.R.

Samara State Medical University

Davydkin I.L.

Samara State Medical University

SPIN RSCI: 1830-7497
Scopus AuthorID: 24337358600
ResearcherID: JWO-4056-2024
ORCID: 0000-0002-4318-4247

Shavlovskaya O.A.

International University of Restorative Medicine», Moscow, Russia

SPIN RSCI: 5300-4282
ORCID: 0000-0003-3726-0730

Received:

01.03.2021

Accepted:

07.04.2021

List of references:

World Health Organization. Coronavirus disease 2019 (‎COVID-19)‎: situation report, 55. Geneva: World Health Organization; 2020.
Hozhabri H, Sparascio FS, Sohrabi H, Mousavifar L, Roy R, Scribano D, De Luca A, Ambrosi C, Sarshar M. The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting. Int J Environ Res Public Health. 2020;17(16):5648. https://doi.org/10.3390/ijerph17165648
Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, Sun J, Chang C. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020;109:102434-102434.
Talotta R., Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic, World J Clin Cases. 2020;8(17):3621-3644. Published online 2020 Sep 6. https://doi.org/10.12998/wjcc.v8.i17.3621
Li C, Wang LL. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. J. Virus Research, 2020;286:198073. https://doi.org/10.1016/j.virusres.2020.198073
Zheng L, Zhang L, Huang J, Nandakumar KS, Liu Sh, Cheng K. Potential treatment methods targeting 2019-nCoV infection. Eur J Med Chem. 2020;205:112687. https://doi.org/10.1016/j.ejmech.2020.112687
Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Donald N. Pharmaco-Immunomodulatory Therapy in COVID-19. Forthal Drugs. 2020;;80(13):1267-1292. https://doi.org/10.1007/s40265-020-01367-z
Abbot NC. Chronic fatigue syndrome. Lancet. 2006;67(9522):1574.
Kotova OV, Akarachkova ES. Asthenic syndrome in the practice of a neurologist and family doctor. RMG. 2016;13:824-829. (In Russ.).
Dyukova GM. Asthenic syndrome: problems of diagnosis and therapy. Effective Neurology and Psychiatry. 2012;1:16-22. (In Russ.).
Poverennova I.E., Zolotovskaya I.A., Bezgina E.V. Diagnostics and treatment of asthenic syndrome in elderly people with acute respiratory viral infections. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;5:7-14. (In Russ.). 2014;114(9):73-76.
Shavlovskaya OA. Therapy of asthenic conditions in patients after stroke. Pharmateca. 2013;19:56-61. (In Russ.).
Zinchuk AN, Zubach EA, Orfin AYa, Plevachuk OYu. Asthenic syndrome and its correction in patients with infectious pathology. Family Medicine. 2019;4(84):41-46. (In Russ.).
Maslennikova NA, Tikhonova EP, Mikhailova LA. Clinical aspects of liver echinococcosis. Modern problems of Science and Education. 2018;5:22. (In Russ.).
Vorobyova YuD, Dyukova GM. Asthenic syndrome in the context of the COVID-19 pandemic. Medical Alphabet. 2020;33:26-34. (In Russ.).
Gestikova MG, Gerasimenko MYu, Kan SL, Minenkov VA, Aikina TP. Management of patients with asthenic syndrome who underwent COVID-19. Doctor. 2020;31:29-32. (In Russ.).
Pennisi M, Lanza G, Falzone L, Fisicaro F, Ferri R, Bella R. SARS-CoV-2 and the nervous system: from clinical features to molecular mechanisms. Int J Mol Sci. 2020;21(15):5475.
Brown E, Gray R, Lo Monaco S, O’Donoghue B, Nelson B, Thompson A. The potential impact of COVID-19 on psychosis: a rapid review of contemporary epidemic and pandemic research. Schizophr Res. 2020;S0920—9964(20)30257-7.
Trejo-Gabriel-Galán JM. Stroke as a complication and prognostic factor of COVID-19. Neurología. 2020;35(5):318-322.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. Front Cell Neurosci. 2018;12:386.
Smets EM, Garssen BJ, Bonke B, DeHaes JC. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. Journal of Psychosomatic Research. 1995;39:315-325. https://doi.org/10.1016/0022-3999(94)00125-O
Kérdö I. Ein aus Daten der Blutzirkulation kalkulierter Index zur Beurteilung der vegetativen Tonuslage. Acta neurovegetativa. 1966;29(2):250-268.
Folstein MF, Folstein SE, McHugh PR. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 175:12(3):189-198.
Preobrazhenskaya IS. Light and moderate cognitive disorders — clinical manifestations, etiology, pathogenesis, the possibility of using nootropic therapy. Farmateka. 2013;4-13:14-18. (In Russ.).
Aristides Tsatsakis, Daniela Calina, Luca Falzone, Dimitrios Petrakis, Radu Mitrut, Vasileios Siokas, Manuela Pennisi, Giuseppe Lanza, Massimo Libra, Sotirios G. Doukas, Panagiotis G. Doukas, Leena Kavali, Amar Bukhari, Chiranjeevi Gadiparthi, Dimitra P. Vageli, Diamantis P. Kofteridis, Demetrios A. Spandidos, Monica M.B. Paoliello, Michael Aschner, Anca Oana Docea SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19 . J.Food Chem Toxicol. 2020;146:111769. Published online 2020 Sep 30. https://doi.org/10.1016/j.fct.2020.111769

Close metadata